News Releases

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
6/12/2018
8:30 AM ET
Press Release

Diffusion Pharmaceuticals Announces Validation of European Patent for Oral Formulations of TSC

6/12/2018

CHARLOTTESVILLE, Va., June 12, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the li...

 Continue Reading
5/29/2018
1:04 PM ET
Earnings Release

CORRECTION: Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

5/29/2018

In the release issued under the same headline on May 10, 2018 by Diffusion Pharmaceuticals Inc. (Nasdaq:DFFN), please note that in the Consolidated Balance Sheets table, Cash and cash equivalents row,...

 Continue Reading
5/10/2018
4:05 PM ET
Press Release

Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

5/10/2018

Patient screening and enrollment are underway in Phase 3 inoperable GBM brain cancer trialKey U.S. Patent IssuedClinical trial preparations are ongoing for Phase 2 trial with TSC in strokeCHARLOTTESVI...

 Continue Reading
4/3/2018
7:30 AM ET
Earnings Release

Diffusion Pharmaceuticals Reports 2017 Financial Results and Provides Business Update

4/3/2018

Patient Enrollment in Phase 3 Inoperable GBM Brain Cancer Trial Underway Raised $12 Million in Underwritten Public Offering Preparing to Commence Clinical Trial with TSC in StrokeExpanded Intellectual...

 Continue Reading
2/6/2018
4:00 PM ET
Press Release

Diffusion Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference

2/6/2018

CHARLOTTESVILLE, Va., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the li...

 Continue Reading
2/1/2018
8:15 AM ET
Press Release

Diffusion Pharmaceuticals Announces Allowances of Two U.S. Patent Applications

2/1/2018

CHARLOTTESVILLE, Va., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc.(NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the li...

 Continue Reading
Displaying 1 to 7 (of 97 releases)